Disease · MONDO_0010643
acute leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. acute leukemia. Diseases, record MONDO_0010643. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010643
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- acute leukaemia (disease), acute leukemia (disease), stem cell leukaemia, stem cell leukemia, stem cell leukemia (disease)
- Open Targets
Drugs118
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CRISANTASPASE | CHEMBL2108931 | Enzyme | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 36 | 36 | 36 | Drugs and targets |
| BUSULFAN | CHEMBL820 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 24 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 3 | ClinicalTrials.gov | 9 | 9 | 0 | Drugs and targets | |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PLERIXAFOR | CHEMBL18442 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 118
See all 118 drugsTargets246
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 5 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 4 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase small subunit mRNA antisense inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6241 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 4 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/50484 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
1 to 10 of 246
See all 246 targetsTrials140
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | Phase 2 | 442 | 2018-12-31 | Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome | SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00081939 | UARK 2003-33, Total Therapy III | Phase 2 | 303 | 2015-10-21 | Multiple Myeloma | BORTEZOMIB, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01810588 | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | Phase 2 | 270 | 2024-10-09 | Hematologic Malignancies | FLUDARABINE, MELPHALAN, MYCOPHENOLATE MOFETIL, RITUXIMAB, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | Phase 2 | 202 | 2022-10-07 | Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | CYCLOSPORINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 3 | 187 | 2025-09-26 | Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome | TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | Not applicable | 174 | 2021-04-22 | Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Neuroblastoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Regional Neuroblastoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia | BUSULFAN, CARBOPLATIN, CARMUSTINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, MELPHALAN, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | Phase 2 | 130 | 2023-02-17 | Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome (MDS) | CYCLOSPORINE, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, TREOSULFAN | Its record names the disease | ClinicalTrials.gov |
| NCT00587054 | Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders | Phase 2 | 129 | 2017-03-10 | Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH) | FLUDARABINE, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT00378534 | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | Phase 2 | 116 | 2015-01-06 | Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | Phase 2 | 86 | 2022-12-08 | Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma, Chronic Myelogenous Leukemia, Hodgkins Lymphoma | CYCLOPHOSPHAMIDE, FLUDARABINE, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 140
See all 140 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Orca-T vs Standard of Care: deaths from any cause | 3 of 88 | 9 of 94 | 182 | NCT05316701 | Trial comparisons |
| Orca-T vs Standard of Care: serious adverse events | 34 of 88 | 53 of 94 | 182 | NCT05316701 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants With Graft Failure/Rejection | 2 of 66 | 5 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants Surviving by 1 Year | 51 of 66 | 47 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Patients With Non-relapse Mortality (NRM) | 7 of 66 | 6 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants Surviving up to 2 Years Without Disease Progression | 37 of 66 | 41 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Non-relapse Mortality | 8 of 66 | 10 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Incidence of Acute or Chronic Graft-versus-host Disease (GVHD) | 7 of 66 | 6 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Incidence of Clinically Significant Infections | 53 of 66 | 61 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants With Secondary Graft Failure | 0 of 66 | 0 of 64 | 130 | NCT00796068 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials64
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010643
GET https://conductscience.org/api/diseases/v1/MONDO_0010643/drugs?page=2